Prevymis (letermovir) - Merck (MSD)
Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. (PubMed, Lancet Infect Dis) - Apr 7, 2025 - "Management recommendations include diagnostics, such as immune monitoring, antiviral prophylaxis with letermovir, management of resistant and refractory CMV infections, and paediatric aspects of CMV management. Furthermore, the 10th ECIL introduced recommendations for two new categories: patients treated with chimeric antigen receptor T cells or treated with bispecific T-cell-engaging antibodies." 
Journal • Review • Cytomegalovirus Infection • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/40188837
 
Alicja Sadowska-Klasa; David Navarro; Federica Galaverna; Hans H Hirsch; Hermann Einsele; Jan Styczynski; Per Ljungman; Rafael de la Camara; Roy F Chemaly; Sophie Alain
 
Apr 7, 2025
 
Prev Next